Tirzepatide Research Evidence
The Tirzepatide evidence base: trials, journals, and what the data does not yet show.
Key Findings at a Glance
- Tirzepatide is the first dual GIP and GLP-1 receptor agonist approved for clinical use, combining two incretin pathways that were previously only targeted individually. • In the SURMOUNT-1 trial, tirzepatide at the 15 mg dose produced average weight loss of 22.5 percent, with over one third of participants losing at least 25 percent of body weight. • Head-to-head trials showed tirzepatide achieves approximately double the weight loss of semaglutide and brings 46 percent of diabetic patients to a normal HbA1c below 5.7 percent versus 19 percent with semaglutide. • The SUMMIT trial demonstrated tirzepatide reduces heart failure events by 38 percent in patients with obesity-related heart failure with preserved ejection fraction, expanding its indications beyond metabolism.
Trials and reviews
- SURMOUNT-OSANEJM2024
AHI -27 vs -5 placebo · OSA-with-obesity only · downstream effect of weight loss, not direct sleep mechanism · N=469
- SUMMITNEJM2024
HFpEF event reduction + symptom benefit · N=731
- SURMOUNT-2Lancet2023
-15.7% in T2D @ 72wk · N=938
- SURMOUNT-1NEJM2022
-22.5% body weight @ 72wk @ 15mg · N=2539
References
- Tirzepatide Once Weekly for the Treatment of Obesity
- Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515.
- Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics.
- Tirzepatide - StatPearls - NCBI Bookshelf
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
- Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.
- Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626.
- Mounjaro FDA Label
- Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021;398(10295):143-155.
- Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.
- FDA Approves First Medication for Obstructive Sleep Apnea
- Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness. Cardiovasc Diabetol. 2022;21(1):66.